Press

Exosome Diagnostics has been awarded coverage by Humana effective April, 1, 2021. Humana is the nation's largest Medicare Advantage provider serving an estimated 20 million patients in the United States.

This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies.

Dr. James McKiernan, Professor of Urology at Columbia University, demonstrated that using the ExoDx Prostate test, or EPI, resulted in good performance ruling out high-grade (Gleason 7 or higher) prostate cancer (HGPCa) in prior negative biopsy patients with the previously validated 15.6 cut-point.

Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr.

Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now offers the ExoCovid-19 test for detection of the virus in patient samples.

Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight against prostate cancer.

Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL

Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection Kit for patients who are concerned about their prostate health.

Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDxTM Prostate (EPI) test for men.